Selinexor Maintenance Post CAR-T Cell Therapy

Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
20 patients (estimated)
Sponsors
Washington University School of Medicine
Collaborators
Karyopharm Therapeutics
Tags
Post-CAR T, Maintenance, High Risk
Trial Type
Treatment
Last Update
SparkCures ID
2184
NCT Identifier
NCT07200102

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.